Lantheus (LNTH) said Tuesday that the US Food and Drug Administration granted final approval for Bravnetsa, a radiopharmaceutical equivalent to Lutathera, for adults with gastroenteropancreatic neuroendocrine tumors, a group of rare cancers affecting the digestive tract and pancreas.
The company said the FDA determined Bravnetsa is the only radiopharmaceutical that is both bioequivalent and therapeutically equivalent to Lutathera, the reference product.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.